AbbVie Historical Income Statement

ABBV Stock

USD 181.77 1.16 0.63%

Historical analysis of AbbVie income statement accounts such as Interest Expense of 1.1 B, Selling General Administrative of 7.8 B or Total Revenue of 33.8 B can show how well AbbVie Inc performed in making a profits. Evaluating AbbVie income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AbbVie's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AbbVie Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AbbVie Inc is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About AbbVie Income Statement Analysis

AbbVie Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AbbVie shareholders. The income statement also shows AbbVie investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AbbVie Income Statement Chart

At this time, AbbVie's Depreciation And Amortization is fairly stable compared to the past year. EBIT is likely to climb to about 10.7 B in 2024, whereas Selling General Administrative is likely to drop slightly above 7.8 B in 2024.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Cost Of Revenue Minority Interest

Total Revenue

Total revenue comprises all receipts AbbVie Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of AbbVie Inc minus its cost of goods sold. It is profit before AbbVie operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AbbVie Inc. It is also known as AbbVie overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on AbbVie Inc income statement and represents the costs associated with goods and services AbbVie provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of AbbVie Inc whose combined shares represent less than 50% of the total outstanding shares issued by AbbVie have a minority interest in AbbVie.

Most accounts from AbbVie's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

	2021	2022	2023	2024 (projected)
Gross Profit	38.8B	40.6B	33.9B	24.3B
Total Revenue	56.2B	58.1B	54.3B	33.8B

Gross Profit Total Revenue

AbbVie income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Minority Interest	Selling And Marketing Expenses
Depreciation And Amortization		0.73	0.8	0.82	0.77	0.83	0.69	0.61	0.43	0.78	0.96	0.73	0.45	-0.83	0.52	0.24	0.55	0.79	-0.66	-0.17	-0.3	-0.86	0.96	0.69	-0.99	0.99
Interest Expense	0.73		0.84	0.96	0.96	0.94	0.89	0.84	0.77	0.9	0.81	0.91	0.53	-0.86	0.64	0.27	0.66	0.82	-0.83	-0.38	-0.76	-0.9	0.85	0.84	-0.75	0.8
Selling General Administrative	0.8	0.84		0.92	0.91	0.93	0.76	0.73	0.64	0.85	0.8	0.93	0.49	-0.72	0.57	0.18	0.6	0.72	-0.61	-0.18	-0.5	-0.79	0.88	0.7	-0.82	0.83
Total Revenue	0.82	0.96	0.92		0.99	0.98	0.91	0.84	0.75	0.93	0.86	0.95	0.62	-0.81	0.71	0.24	0.73	0.8	-0.72	-0.25	-0.68	-0.89	0.93	0.84	-0.85	0.87
Gross Profit	0.77	0.96	0.91	0.99		0.96	0.93	0.88	0.77	0.94	0.82	0.95	0.68	-0.78	0.76	0.23	0.79	0.75	-0.7	-0.25	-0.73	-0.88	0.88	0.85	-0.81	0.82
Other Operating Expenses	0.83	0.94	0.93	0.98	0.96		0.82	0.75	0.78	0.88	0.87	0.97	0.5	-0.81	0.6	0.16	0.62	0.83	-0.71	-0.32	-0.62	-0.87	0.93	0.84	-0.85	0.88
Operating Income	0.69	0.89	0.76	0.91	0.93	0.82		0.95	0.58	0.96	0.74	0.76	0.84	-0.71	0.88	0.42	0.89	0.63	-0.67	-0.05	-0.73	-0.84	0.81	0.73	-0.74	0.75
Ebit	0.61	0.84	0.73	0.84	0.88	0.75	0.95		0.52	0.95	0.64	0.71	0.83	-0.64	0.9	0.38	0.91	0.61	-0.67	-0.14	-0.78	-0.82	0.72	0.69	-0.64	0.64
Research Development	0.43	0.77	0.64	0.75	0.77	0.78	0.58	0.52		0.54	0.61	0.87	0.31	-0.57	0.44	-0.16	0.46	0.52	-0.47	-0.52	-0.69	-0.57	0.55	0.84	-0.49	0.51
Ebitda	0.78	0.9	0.85	0.93	0.94	0.88	0.96	0.95	0.54		0.78	0.81	0.76	-0.74	0.84	0.37	0.85	0.76	-0.72	-0.15	-0.68	-0.91	0.88	0.73	-0.8	0.81
Cost Of Revenue	0.96	0.81	0.8	0.86	0.82	0.87	0.74	0.64	0.61	0.78		0.81	0.46	-0.89	0.53	0.23	0.57	0.77	-0.71	-0.26	-0.46	-0.86	0.94	0.81	-0.97	0.97
Total Operating Expenses	0.73	0.91	0.93	0.95	0.95	0.97	0.76	0.71	0.87	0.81	0.81		0.46	-0.74	0.57	0.04	0.6	0.74	-0.63	-0.37	-0.64	-0.8	0.84	0.85	-0.77	0.79
Income Before Tax	0.45	0.53	0.49	0.62	0.68	0.5	0.84	0.83	0.31	0.76	0.46	0.46		-0.28	0.96	0.45	0.95	0.22	-0.23	0.31	-0.57	-0.52	0.54	0.42	-0.54	0.48
Total Other Income Expense Net	-0.83	-0.86	-0.72	-0.81	-0.78	-0.81	-0.71	-0.64	-0.57	-0.74	-0.89	-0.74	-0.28		-0.4	-0.17	-0.45	-0.85	0.93	0.46	0.49	0.89	-0.84	-0.82	0.8	-0.85
Net Income	0.52	0.64	0.57	0.71	0.76	0.6	0.88	0.9	0.44	0.84	0.53	0.57	0.96	-0.4		0.25	0.99	0.39	-0.38	0.05	-0.63	-0.67	0.61	0.59	-0.58	0.54
Income Tax Expense	0.24	0.27	0.18	0.24	0.23	0.16	0.42	0.38	-0.16	0.37	0.23	0.04	0.45	-0.17	0.25		0.25	0.09	-0.19	0.52	-0.3	-0.17	0.27	-0.16	-0.27	0.27
Net Income From Continuing Ops	0.55	0.66	0.6	0.73	0.79	0.62	0.89	0.91	0.46	0.85	0.57	0.6	0.95	-0.45	0.99	0.25		0.4	-0.4	0.03	-0.65	-0.69	0.63	0.63	-0.61	0.57
Non Recurring	0.79	0.82	0.72	0.8	0.75	0.83	0.63	0.61	0.52	0.76	0.77	0.74	0.22	-0.85	0.39	0.09	0.4		-0.85	-0.53	-0.47	-0.92	0.85	0.74	-0.73	0.81
Non Operating Income Net Other	-0.66	-0.83	-0.61	-0.72	-0.7	-0.71	-0.67	-0.67	-0.47	-0.72	-0.71	-0.63	-0.23	0.93	-0.38	-0.19	-0.4	-0.85		0.56	0.54	0.87	-0.7	-0.74	0.61	-0.68
Tax Provision	-0.17	-0.38	-0.18	-0.25	-0.25	-0.32	-0.05	-0.14	-0.52	-0.15	-0.26	-0.37	0.31	0.46	0.05	0.52	0.03	-0.53	0.56		0.24	0.43	-0.19	-0.61	0.1	-0.18
Interest Income	-0.3	-0.76	-0.5	-0.68	-0.73	-0.62	-0.73	-0.78	-0.69	-0.68	-0.46	-0.64	-0.57	0.49	-0.63	-0.3	-0.65	-0.47	0.54	0.24		0.59	-0.45	-0.61	0.36	-0.38
Net Interest Income	-0.86	-0.9	-0.79	-0.89	-0.88	-0.87	-0.84	-0.82	-0.57	-0.91	-0.86	-0.8	-0.52	0.89	-0.67	-0.17	-0.69	-0.92	0.87	0.43	0.59		-0.9	-0.84	0.83	-0.87
Reconciled Depreciation	0.96	0.85	0.88	0.93	0.88	0.93	0.81	0.72	0.55	0.88	0.94	0.84	0.54	-0.84	0.61	0.27	0.63	0.85	-0.7	-0.19	-0.45	-0.9		0.76	-0.96	0.98
Extraordinary Items	0.69	0.84	0.7	0.84	0.85	0.84	0.73	0.69	0.84	0.73	0.81	0.85	0.42	-0.82	0.59	-0.16	0.63	0.74	-0.74	-0.61	-0.61	-0.84	0.76		-0.72	0.73
Minority Interest	-0.99	-0.75	-0.82	-0.85	-0.81	-0.85	-0.74	-0.64	-0.49	-0.8	-0.97	-0.77	-0.54	0.8	-0.58	-0.27	-0.61	-0.73	0.61	0.1	0.36	0.83	-0.96	-0.72		-0.99
Selling And Marketing Expenses	0.99	0.8	0.83	0.87	0.82	0.88	0.75	0.64	0.51	0.81	0.97	0.79	0.48	-0.85	0.54	0.27	0.57	0.81	-0.68	-0.18	-0.38	-0.87	0.98	0.73	-0.99

Click cells to compare fundamentals

AbbVie Account Relationship Matchups

AbbVie income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	6.5B	8.5B	8.5B	8.7B	9.1B
Interest Expense	1.5B	2.5B	2.4B	2.2B	2.2B	1.1B
Selling General Administrative	5.8B	9.5B	10.2B	13.3B	10.7B	7.8B
Total Revenue	33.3B	45.8B	56.2B	58.1B	54.3B	33.8B
Gross Profit	25.8B	30.4B	38.8B	40.6B	33.9B	24.3B
Other Operating Expenses	19.9B	34.4B	38.3B	39.9B	41.6B	23.7B
Operating Income	13.0B	11.4B	17.9B	18.1B	12.8B	9.8B
Ebit	13.8B	14.7B	19.8B	23.0B	8.6B	10.7B
Research Development	6.4B	6.6B	7.1B	6.5B	8.5B	5.5B
Ebitda	13.8B	21.1B	28.3B	31.4B	17.3B	13.5B
Cost Of Revenue	7.4B	15.4B	17.4B	17.4B	20.4B	21.4B
Total Operating Expenses	12.5B	17.9B	19.9B	21.8B	21.1B	14.0B
Income Before Tax	8.4B	3.4B	13.0B	13.5B	6.3B	7.3B
Total Other Income Expense Net	(4.6B)	(8.0B)	(4.9B)	(4.6B)	(6.5B)	(6.2B)
Net Income	7.9B	4.6B	11.5B	11.8B	4.9B	6.3B
Income Tax Expense	544M	1.2B	1.4B	1.6B	1.4B	1.2B
Net Income Applicable To Common Shares	7.9B	4.6B	11.5B	11.8B	13.6B	14.3B
Net Income From Continuing Ops	7.9B	4.6B	11.5B	11.8B	4.9B	6.9B
Non Recurring	385M	1.2B	962M	697M	801.6M	553.6M
Non Operating Income Net Other	(3.0B)	(5.7B)	(2.6B)	(2.6B)	(2.3B)	(2.5B)
Tax Provision	544M	(1.2B)	1.4B	1.6B	1.4B	811.5M
Interest Income	275M	174M	39M	186M	540M	567M
Net Interest Income	(1.5B)	(2.3B)	(2.4B)	(2.0B)	(1.7B)	(1.8B)
Reconciled Depreciation	2.0B	6.5B	8.5B	8.5B	8.7B	5.9B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AbbVie Historical Income Statement

About AbbVie Income Statement Analysis

AbbVie Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Cost Of Revenue

Minority Interest

AbbVie income statement Correlations

AbbVie Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AbbVie income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for AbbVie Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Selling And Marketing Expenses	+ 0.99	Depreciation And Amortization
Gross Profit	+ 0.99	Total Revenue
Net Income From Continuing Ops	+ 0.99	Net Income
Other Operating Expenses	+ 0.98	Total Revenue
Selling And Marketing Expenses	+ 0.98	Reconciled Depreciation
Total Operating Expenses	+ 0.97	Other Operating Expenses

Selling And Marketing Expenses	- 0.99	Minority Interest
Minority Interest	- 0.99	Depreciation And Amortization
Minority Interest	- 0.97	Cost Of Revenue
Minority Interest	- 0.96	Reconciled Depreciation
Net Interest Income	- 0.92	Non Recurring
Net Interest Income	- 0.91	Ebitda